Boston Scientific Corpora... (BSX)
Boston Scientific Statistics
Share Statistics
Boston Scientific has 1.48B shares outstanding. The number of shares has increased by 0.6% in one year.
| Shares Outstanding | 1.48B |
| Shares Change (YoY) | 0.6% |
| Shares Change (QoQ) | 0.36% |
| Owned by Institutions (%) | 90.51% |
| Shares Floating | 1.47B |
| Failed to Deliver (FTD) Shares | 20 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 14.4M, so 0.98% of the outstanding shares have been sold short.
| Short Interest | 14.4M |
| Short % of Shares Out | 0.98% |
| Short % of Float | 0.98% |
| Short Ratio (days to cover) | 2.76 |
Valuation Ratios
The PE ratio is 70.93 and the forward PE ratio is 36.41. Boston Scientific's PEG ratio is 4.26.
| PE Ratio | 70.93 |
| Forward PE | 36.41 |
| PS Ratio | 7.85 |
| Forward PS | 5.4 |
| PB Ratio | 6.04 |
| P/FCF Ratio | 49.69 |
| PEG Ratio | 4.26 |
Enterprise Valuation
Boston Scientific has an Enterprise Value (EV) of 141.77B.
| EV / Sales | 8.47 |
| EV / EBITDA | 54.46 |
| EV / EBIT | 41.27 |
| EV / FCF | 53.6 |
Financial Position
The company has a current ratio of 1.08, with a Debt / Equity ratio of 0.49.
| Current Ratio | 1.08 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | 4.13 |
| Debt / FCF | 4.06 |
| Interest Coverage | 8.53 |
Financial Efficiency
Return on Equity is 8.51% and Return on Invested Capital is 6.06%.
| Return on Equity | 8.51% |
| Return on Assets | 4.7% |
| Return on Invested Capital | 6.06% |
| Revenue Per Employee | $315.98K |
| Profits Per Employee | $34.96K |
| Employee Count | 53,000 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.87 |
Taxes
| Income Tax | 436M |
| Effective Tax Rate | 19.11% |
Stock Price Statistics
The stock price has increased by 45.61% in the last 52 weeks. The beta is 0.73, so Boston Scientific's price volatility has been higher than the market average.
| Beta | 0.73 |
| 52-Week Price Change | 45.61% |
| 50-Day Moving Average | 102.04 |
| 200-Day Moving Average | 88.57 |
| Relative Strength Index (RSI) | 43.72 |
| Average Volume (20 Days) | 7.8M |
Income Statement
In the last 12 months, Boston Scientific had revenue of 16.75B and earned 1.85B in profits. Earnings per share was 1.26.
| Revenue | 16.75B |
| Gross Profit | 11.49B |
| Operating Income | 2.6B |
| Net Income | 1.85B |
| EBITDA | 2.6B |
| EBIT | 2.59B |
| Earnings Per Share (EPS) | 1.26 |
Balance Sheet
The company has 414M in cash and 10.75B in debt, giving a net cash position of -10.33B.
| Cash & Cash Equivalents | 414M |
| Total Debt | 10.75B |
| Net Cash | -10.33B |
| Retained Earnings | 2.67B |
| Total Assets | 39.4B |
| Working Capital | 521M |
Cash Flow
In the last 12 months, operating cash flow was 3.44B and capital expenditures -790M, giving a free cash flow of 2.65B.
| Operating Cash Flow | 3.44B |
| Capital Expenditures | -790M |
| Free Cash Flow | 2.65B |
| FCF Per Share | 1.8 |
Margins
Gross margin is 68.61%, with operating and profit margins of 15.54% and 11.06%.
| Gross Margin | 68.61% |
| Operating Margin | 15.54% |
| Pretax Margin | 13.63% |
| Profit Margin | 11.06% |
| EBITDA Margin | 15.54% |
| EBIT Margin | 15.54% |
| FCF Margin | 15.79% |
Dividends & Yields
BSX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 1.41% |
| FCF Yield | 2.01% |
Analyst Forecast
The average price target for BSX is $110, which is 11.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $110 |
| Price Target Difference | 11.5% |
| Analyst Consensus | Buy |
| Analyst Count | 23 |
Stock Splits
The last stock split was on Nov 6, 2003. It was a forward split with a ratio of 2:1.
| Last Split Date | Nov 6, 2003 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 5.92 |
| Piotroski F-Score | 5 |